Medicine & Life Sciences
Cost-Benefit Analysis
100%
Costs and Cost Analysis
85%
Quality-Adjusted Life Years
68%
ribociclib
39%
Prostatic Neoplasms
35%
olaparib
34%
niraparib
27%
Castration
24%
atezolizumab
23%
Drosophila
23%
pembrolizumab
20%
abiraterone
20%
Therapeutics
19%
Nociceptors
19%
Breast Neoplasms
19%
human ERBB2 protein
19%
Placebos
18%
Health Care Costs
17%
Larva
17%
Type 2 Diabetes Mellitus
16%
Patient Preference
16%
Platinum
16%
Insurance
15%
Economics
14%
Drug Therapy
14%
Nociception
14%
Ovarian Neoplasms
13%
Non-Small Cell Lung Carcinoma
13%
Systemic Scleroderma
13%
avelumab
12%
durvalumab
12%
daratumumab
12%
Global Burden of Disease
12%
cabazitaxel
12%
Axitinib
11%
130-nm albumin-bound paclitaxel
11%
Wasps
11%
Systematic Reviews
10%
MDV 3100
10%
Ipilimumab
10%
Hot Temperature
10%
Progression-Free Survival
10%
Nivolumab
10%
Fulvestrant
9%
Lenalidomide
9%
Sunitinib
9%
Pharmaceutical Services
9%
Drug Costs
9%
Drosophila melanogaster
9%
Bortezomib
9%
Social Sciences
cancer
40%
costs
31%
life years
15%
chronic illness
14%
Commercial insurance
12%
utility analysis
11%
impact analysis
10%
willingness to pay
8%
medication
8%
economic impact
7%
death
7%
pharmaceutical
6%
expenditures
6%
adverse events
6%
budget
5%
incentive
5%
drug
5%